GlassScriptPhysician profile
Vishal Sehgal
NPI 1932270253
$1,544.89
in general payments reported to CMS, 2019-2025
20 companies · $448 in 2025
The $448 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $54.45 · 2022: $21.49 · 2023: $245 · 2024: $431 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.22 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $202.90 | 2023-2024 | Signia, Minimed 780g |
| Beta Bionics, INC. | $171.03 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Medtronic Minimed, INC. | $170.15 | 2019-2020 | |
| Corcept Therapeutics | $157.57 | 2019-2025 | Korlym |
| Sequel Med Tech, LLC | $131.58 | 2025 | Twiist |
| Angiodynamics, INC. | $122.27 | 2024 | Angiovac |
| Novo Nordisk INC | $121.18 | 2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $94.34 | 2023 | |
| Tandem Diabetes Care, INC. | $64.30 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $53.95 | 2019 | |
| Abbott Laboratories | $45.06 | 2022-2023 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $39.16 | 2019 | |
| Mannkind Corporation | $33.11 | 2019-2023 | Afrezza |
| Ascensia Diabetes Care US INC. | $28.16 | 2023 | |
| Sanofi-Aventis U.S. LLC | $27.84 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $25.36 | 2019 | |
| Shire North American Group INC | $15.50 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.29 | 2019 | |
| Lilly USA, LLC | $13.91 | 2019 | |
| Merck Sharp & Dohme LLC | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishal Sehgal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.